| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Cholesteryl linoleate targets lipid metabolism pathways. As a major cholesterol ester in LDL, it is involved in cholesterol transport and metabolism. Receptor-LDL complexes are taken up by lysosomes and hydrolyzed to release cholesterol from the esters. The compound undergoes oxidation to form cholesteryl linoleate hydroperoxides. It is a pro-atherogenic cholesterol ester. Cholesteryl linoleate is used to study cholesterol to phospholipid ratio in red blood cell membranes.
|
|---|---|
| ln Vitro |
In vitro, Cholesteryl linoleate is used to study cholesterol to phospholipid ratio in red blood cell membranes. It is a major cholesterol ester found in LDL. The compound is used in lipid research to study cholesterol ester metabolism and transport. It undergoes oxidation to form cholesteryl linoleate hydroperoxides. Cholesteryl linoleate is a component of LDL in macrophage plasma membranes.
|
| ln Vivo |
In vivo, Cholesteryl linoleate is a major cholesterol ester in LDL and has a role as a human metabolite. Receptor-LDL complexes are taken up by lysosomes and hydrolyzed to release cholesterol. The compound is pro-atherogenic and undergoes oxidation. It is used in research on atherosclerosis and lipid metabolism. Further in vivo studies have evaluated its role in cardiovascular disease.
|
| Enzyme Assay |
In vitro enzyme assays for Cholesteryl linoleate involve measuring its hydrolysis by lysosomal acid lipase. Enzyme activity is assessed by measuring the release of cholesterol and linoleic acid from the ester. Oxidation of cholesteryl linoleate is assessed by measuring hydroperoxide formation. For lipid membrane studies, the compound is used to prepare dispersions with cholesterol to study membrane properties. Assays are performed in appropriate buffer systems with positive controls.
|
| Cell Assay |
In vitro cell-based assays for Cholesteryl linoleate are conducted in macrophages and other cell types. Cells are cultured in appropriate media and treated with the compound. Cholesterol ester accumulation in cells is measured by lipid staining or biochemical assays. LDL uptake and metabolism are assessed. Cell viability is assessed by standard assays. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
Cholesteryl linoleate in vivo studies are conducted in animal models of atherosclerosis. Animals are fed high-fat diets containing Cholesteryl linoleate. Atherosclerotic plaque formation is assessed. Lipid profiles and cholesterol ester levels in blood and tissues are measured. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biochemical analysis at study endpoints. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Cholesteryl linoleate (MW 649.08-649.09 g/mol, C45H76O2) is a major cholesterol ester in LDL. It is a liquid crystal (LC) material. The compound has a purity of 95%. It is a human and mouse metabolite. Cholesteryl linoleate is used in lipid and atherosclerosis research. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies.
|
| Toxicity/Toxicokinetics |
Cholesteryl linoleate is generally well-tolerated as an endogenous lipid. The compound is a major cholesterol ester in LDL with established metabolic roles. Its pro-atherogenic properties are related to its role in atherosclerosis. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Cholesteryl linoleate is the (9Z,12Z)-stereomer of Cholesteryl octadec-9,12-dienoate. It is a metabolite in both humans and mice. It is an octadec-9,12-dienoate of Cholesteryl and also a CE (18:2). Functionally, it is related to linoleic acid. Data on the effects of Cholesteryl linoleate in Homo sapiens have been reported.
Cholesteryl linoleate is a major cholesterol ester in LDL and a pro-atherogenic cholesterol ester found in macrophage plasma membranes. It has a role as a human and mouse metabolite. The compound undergoes oxidation to form cholesteryl linoleate hydroperoxides. It is used in atherosclerosis and lipid metabolism research. Its molecular formula is C45H76O2 with a molecular weight of 649.08-649.09 g/mol. All applications are limited to non-human research use. |
| Molecular Formula |
C45H76O2
|
|---|---|
| Molecular Weight |
649.0838
|
| Exact Mass |
648.584
|
| CAS # |
604-33-1
|
| PubChem CID |
5287939
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
677.3±44.0 °C at 760 mmHg
|
| Melting Point |
42ºC
|
| Flash Point |
364.0±16.0 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.517
|
| LogP |
18.17
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
21
|
| Heavy Atom Count |
47
|
| Complexity |
1020
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
CCCCC/C=C\C/C=C\CCCCCCCC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC[C@@H]4[C@H](C)CCCC(C)C)C)C
|
| InChi Key |
NAACPBBQTFFYQB-LJAITQKLSA-N
|
| InChi Code |
InChI=1S/C45H76O2/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-25-43(46)47-38-30-32-44(5)37(34-38)26-27-39-41-29-28-40(36(4)24-22-23-35(2)3)45(41,6)33-31-42(39)44/h11-12,14-15,26,35-36,38-42H,7-10,13,16-25,27-34H2,1-6H3/b12-11-,15-14-/t36-,38+,39+,40-,41+,42+,44+,45-/m1/s1
|
| Chemical Name |
[(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] (9Z,12Z)-octadeca-9,12-dienoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~77.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5406 mL | 7.7032 mL | 15.4064 mL | |
| 5 mM | 0.3081 mL | 1.5406 mL | 3.0813 mL | |
| 10 mM | 0.1541 mL | 0.7703 mL | 1.5406 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
